Articles tagged with Breast Cancer Cells
Breast cancer cells can recycle their components to survive antiestrogen therapy, with macroautophagy playing a key role in this survival strategy. Researchers now believe targeting the autophagosome function could significantly improve hormonal treatment for estrogen-positive breast cancer.
Researchers at Baylor College of Medicine discovered three phosphatases that deactivate cancer-promoting molecule SRC-3. This finding provides a new target for cancer treatment and may lead to more effective drugs with fewer side effects.
Researchers have created a rapid cell inspection technique that can identify metastatic breast cancer cells, which have compromised the cell's structure and compromise deformation. The technique uses an electrical field within a microscopic fluid-filled channel and has been shown to expand cells by 75% in metastatic cases.
A new advance in cellular imaging allows scientists to track the movement of live cells in the area around tumors, providing insights into how certain immune cells help or hinder tumor growth. This study sheds light on potential drug targets and mechanisms to enhance the body's natural immune response to cancer.
Researchers at McGill University have discovered a way to make cancer vulnerable to viruses using a new compound called histone deacetylase inhibitors. This approach has the potential to overcome resistance and increase the effectiveness of viral 'magic bullets' in targeting cancer cells.
Australian scientists identified four groupings of genes related to breast cancer cell behavior and their impact on tamoxifen treatment. This discovery could help clinicians predict which women will respond well to anti-oestrogen therapies.
Researchers found that IGF-I stimulates aggressive tumor growth and DNA repair regulation, leading to poor outcomes. The study identifies a gene signature linked to patient responses to breast cancer treatments, offering potential biomarkers for targeted therapies.
Researchers at Cold Spring Harbor Laboratory discovered an enzyme called Brk that accelerates HER2-positive tumor growth and contributes to drug resistance. The team found that targeting Brk may provide a safe strategy for treating ErbB2-positive tumors.
Research finds that dense breast tissue promotes aggressive cancer cells, as breast cancer cells in denser surroundings step up their invasive activities. The study suggests a cellular mechanism linking human breast tissue density and tumor aggressiveness.
Researchers at Duke University have synthesized largazole, a marine algae extract with potential as an anti-cancer agent. The team's efficient synthetic route enables the production of gram-sized quantities, paving the way for further study and potential treatment of various cancers.
Researchers at Ohio State University developed synthetic molecules based on curcumin to kill cancer cells and stop cell spread. The compounds show promise in treating 50% of breast and prostate cancers, with potential applications in pancreatic cancer as well.
Researchers at Georgetown University Medical Center have discovered that vitamin A can push stem cells in breast cancer tumors to form endothelial cells, leading to the creation of new blood vessels. This finding supports the 'vasculogenic mimicry' theory, which proposes that tumors build their own blood pipelines.
A new study from the University of Michigan Comprehensive Cancer Center found that HER2-positive breast cancers have four to five times more cancer stem cells than HER2-negative cancers. The drug Herceptin was shown to reduce cancer stem cell numbers by 80 percent, targeting and destroying these cells.
Scientists at Thomas Jefferson University have discovered a key mechanism of breast cancer metastasis, where a gene dubbed 'Dachshund' (DACH1) regulates the production of IL-8, a common inflammatory protein. Blocking this protein with an antibody completely halted breast cancer spread in mice.
Mechanical engineering Professor Adela Ben-Yakar has developed a laser microscalpel that targets individual cancer cells in 3D without damaging surrounding cells. The device uses femtosecond lasers to sear targeted cells quickly and accurately, potentially revolutionizing surgeries for cancer, epilepsy, and other diseases.
A University of Michigan study reveals how the CHFR gene affects breast cell division, leading to genomic instability and cancer. The loss of CHFR disrupts chromosome segregation, creating conditions for cancer cells to grow and thrive.
A new study suggests that weight loss after gastric bypass surgery may improve immune function, protecting against cancer and infections. The study found that surgically induced weight loss increased the activity of natural killer cells, which play a critical role in controlling infections and cancer.
Researchers have identified a new family of compounds that can effectively treat estrogen receptor-positive breast cancers resistant to tamoxifen. The compounds, including TPBM and related agents, work by inhibiting the growth of cancer cells stimulated by estrogen.
Researchers developed a therapeutic system targeting HIF-1 activated cancer cells, showing success in laboratory tests. The system uses a reporter gene to detect and treat hypoxic cancer cells that are resistant to traditional treatments.
A case of primary rectal signet ring cell carcinoma with peritoneal dissemination and gastric secondaries was reported. The diagnosis relied on immunohistochemical studies using cytokeratins 7 and 20, highlighting the importance of accurate pathological techniques in identifying this rare cancer type.
Researchers have identified an embryonic pathway that confers adult stem cell properties to both normal and cancer cells undergoing epithelial-to-mesenchymal transition, offering a potential route to generate unlimited numbers of stem cells. This discovery has major implications for regenerative medicine and cancer treatment.
Researchers at UT Southwestern Medical Center found that methylation acts as a biological clock indicating cell division history and cancer risk. Having children or approaching menopause can turn the clock back, reducing breast cancer risk.
Researchers at the OU Cancer Institute have identified a new gene called RBM3 that causes cancer. The gene is vital for cell division in normal cells but leads to increased tumor formation when overexpressed in cancerous cells.
Researchers discover that myoepithelial cells play a critical role in regulating breast tumor progression and can act as 'gatekeepers' for the transition from in situ to invasive carcinoma. Understanding their pathways may open new avenues for cancer therapy and prevention.
A new study identifies a specific genetic variation in the FGFR2 gene that alters its binding to regulatory proteins, leading to increased expression and an elevated risk of breast cancer. The mutation occurs in non-coding regions of the gene, affecting its regulation rather than protein production.
A new study led by Dana-Farber Cancer Institute researchers found that abnormal surrounding cells cause the walls of the ducts to deteriorate, enabling tumor cells to escape. The discovery may lead to screening tests and treatments targeting genetic abnormalities in cells lining the ducts.
Researchers at M. D. Anderson Cancer Center found that EGFR stabilizes a protein channeling glucose to cancer cells, saving them from starvation. This discovery may require targeting both EGFR's growth-inducing kinase activity and its glucose-related role to effectively treat epithelial cancers.
A mathematical model suggests that women with wild-type CYP2D6 genotype may derive as much benefit from tamoxifen as from aromatase inhibitors, potentially leading to personalized therapy approaches. Additionally, a study finds that cancer stem cells resistant to standard chemotherapy are responsive to targeted therapy.
A team of researchers at UNC Chapel Hill has discovered new targets for cancer treatment by identifying proteins that promote blood vessel formation in tumors. The study found 55 genes overexpressed in breast cancer vessels, offering potential new targets for therapy.
A new drug, lapatinib, has been shown to significantly shrink primary breast cancer tumors in just six weeks by targeting cancer stem cells. This breakthrough finding suggests a possible new therapy for eliminating tumor-causing cells and achieving long-term cancer eradication.
Recent discoveries suggest that stem cells can serve as potential therapeutic targets for many types of cancers. Researchers have identified specific markers, such as aldehyde dehydrogenase, to isolate cancer-initiating cells and track their response to treatment. These findings hold promise for the development of targeted therapies.
A gene associated with human breast stem cells can stimulate the development of mammary cells by activating Wnt and Notch pathways, which are critical to cancer growth. The study suggests that targeting this gene might provide a new way to treat cancers of the breast and other tumor types.
Research suggests that genistein in soy foods reduces the risk of breast cancer by controlling cell growth and death in young women. The exact mechanism is not yet fully understood, but studies suggest a link between soy consumption during puberty and reduced breast cancer risk.
A study by researchers at the University of Mississippi found that consuming green tea's EGCG significantly inhibits breast tumor growth and angiogenesis in female mice. The results suggest that EGCG may provide protection against breast cancer by targeting tumor blood vessels and cells.
A recent study found that the human breast tumor microenvironment can prime cells for metastasis, particularly to the lungs. Researchers discovered a correlation between TGFß exposure and increased risk of lung cancer in ER- tumors.
A study led by Memorial Sloan-Kettering Cancer Center researchers reveals that breast cancer cells use a signaling molecule called TGF-a to enhance their ability to spread to the lungs. This finding has significant implications for developing therapies to prevent metastasis in cancer patients.
Researchers at the University of Missouri found that synthetic hormone replacement therapy can promote breast cancer growth, but an antibody and small molecular drug may prevent tumor cell expansion. The study suggests a potential link between hormone replacement therapy and breast cancer progression.
Researchers at Harvard Medical School have identified proteins that promote tumor growth in certain types of cancer, including breast and ovarian cancer. Targeting these proteins with small molecules may lead to new therapeutic options for patients.
Researchers discovered that SATB1 protein promotes tumor growth and metastasis in breast cancer. High levels of SATB1 expression are associated with poor prognosis, and reducing SATB1 can prevent the formation of invasive cells.
Researchers at EMBL discovered that estrogen causes rapid epigenetic changes in breast cancer cells, challenging the long-held assumption of methylation as a mechanism of long-term gene regulation. This cyclical nature of methylation may shed light on the molecular bases of cancer and development.
A study led by Mary J. C. Hendrix found that the Lefty protein, secreted only in human embryonic stem cells, inhibits growth and spread of melanoma and breast cancer cells. This breakthrough suggests potential therapeutic modalities for cancer treatment and highlights the utility of isolating factors within the embryonic microenvironment.
A University of Florida study found that the protein Bc12 blocks DNA repair in lung cancer cells, allowing them to thrive despite damage from radiation or chemicals. The discovery provides a new understanding of how lung cancer cells evade treatments, offering potential targets for drug development.
Researchers discovered that atypical protein kinase C (aPKC) stabilizes steroid receptor coactivator-3 (SRC-3) levels in breast cancer cells. This stabilization is associated with increased SRC-3 function and enhanced estrogen-receptor target gene transcription.
Research found that DDT's main metabolite, p,p'-DDE, disrupts hormone-sensitive breast cancer cells by opposing the androgen signalling pathway. This suggests a new mechanism for breast cancer progression, potentially favouring tumour growth in women.
A study found that women with ductal carcinoma in situ (DCIS) have overly optimistic views of their risk of recurrence and invasive breast cancer. Anxiety levels decreased over time, but depression remained low. Clinicians should be aware of these inaccurate perceptions to minimize distress.
Researchers found that BRCA1 plays a role in regulating breast stem cells, which can develop into cancers. Women with BRCA1 mutations have a high incidence of breast cancer due to the unregulated proliferation of these stem cells.
Researchers have identified cyclin D1 as a key player in ER+ breast cancers, which are the most common type of breast cancer. The study found that inhibiting cyclin D1 function may provide a new treatment strategy for these tumors.
Researchers at Duke University Medical Center have identified a new pathway involving BRCA1 in repairing damaged DNA, which may explain the increased breast cancer risk in women with mutated BRCA1 genes. This discovery could lead to more effective therapies for women with and without BRCA1 mutations.
A new study by Atsushi Mizoguchi and colleagues established that IL-22 ameliorates disease in a mouse model of ulcerative colitis. The authors suggested that individuals with UC might benefit from local delivery of the IL-22 gene to their intestines.
Researchers at the Salk Institute found that early-stage breast cancer cells with high motility pose an increased risk of metastasis. These cells can wander along milk ducts and seed new tumors within the same breast, suggesting a need for earlier intervention.
Researchers at CSHL have identified and repressed breast cancer stem cells in mouse tissue by manipulating microRNAs, suggesting a potential therapeutic target for breast cancer treatment. The study found that the delivery of the microRNA let-7 to breast-tissue cells can help distinguish stem-like tumor-initiating cells from other cells.
Researchers discovered a genetic switch that regulates critical properties of cancer stem cells using microRNAs. Activating this switch, let-7, can push cancer stem cells to differentiate and lose their tumorigenic abilities, offering a novel approach to targeting these cells with therapeutic RNAs.
A series of genes has been identified as protecting cells from the harmful effects of doxorubicin, a commonly used chemotherapeutic agent. The long-term goal is to develop ways to turn these genes off in cancer cells and on in heart cells to prevent or mitigate heart damage.
A new marker, ALDH1, has been identified that can be used to detect and characterize cancer stem cells in breast tumors. These cells are responsible for fueling a tumor's growth and are linked to worse outcomes.
Researchers at UCLA used Atomic Force Microscopy to measure the softness of living cancer cells from patient samples, distinguishing them from normal cells. This method may aid in diagnosing cancer and personalizing treatments.
Researchers found that the Wwox protein keeps ErbB-4 on the cell surface, associated with better survival in breast-cancer patients. The absence of Wwox is linked to shorter survival, particularly in triple-negative breast cancers.
A new microscope technique offers real-time analysis of breast cancer biopsies, which could reduce the number of needle biopsies needed from women suspected of having breast cancer. The technique uses reflectance confocal microscopy to examine tissue samples and detect cancer cells in minutes.
A study led by UCSF researchers identified p16 and COX-2 biomarkers as predictors of future tumor formation in women with ductal carcinoma in situ (DCIS). The findings suggest that these biomarkers can help determine the best treatment option for DCIS patients.
Locally advanced breast cancer (LABC) may account for 50% of breast cancers in developing countries and 30% among socially disadvantaged women. A new study identifies a molecular switch essential for LABC development, which could be targeted for new therapies.
Researchers found that extracts of channel catfish caught in polluted waters can activate estrogen receptors in breast cancer cells, leading to cell growth. The study suggests that pharmaceutical estrogens and xeno-estrogenic chemicals are contaminating local waterways.